Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate
Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate
Biofrontera 2024 年第一季度公认会计准则每股收益 (2.88 美元) 未达到预期 (1.17) 美元，销售额为 791.2 万美元，低于预期 1,085.7 万美元
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(2.88) per share which missed the analyst consensus estimate of $(1.17) by 146.15 percent. This is a 48.57 percent increase over losses of $(5.60) per share from the same period last year. The company reported quarterly sales of $7.912 million which missed the analyst consensus estimate of $10.857 million by 27.12 percent. This is a 9.40 percent decrease over sales of $8.733 million the same period last year.
Biofrontera（纳斯达克股票代码：BFRI）公布的季度亏损为每股2.88美元，比分析师普遍预期的1.17美元（1.17美元）低146.15％。这比去年同期每股亏损5.60美元（5.60美元）增长了48.57％。该公司公布的季度销售额为791.2万美元，比分析师普遍预期的1,085.7万美元低27.12％。这比去年同期的873.3万美元的销售额下降了9.40％。